Skip to main content

Table 1 Demographic and HIV details of participants

From: HIV viral suppression at different thresholds and duration of treatment in the dolutegravir treatment era in Sierra Leone: a nationwide survey

 

Type of facility

 

Demographic/HIV details

Overall

N (%)

Primary

N (%)

Secondary

N (%)

Tertiary

N (%)

p-value

Age (years)

    

0.20

(0,30]

758 (33.6%)

209 (34.8%)

66 (35.1%)

483 (33.0%)

 

(30,40]

693 (30.8%)

187 (31.1%)

70 (37.2%)

436 (29.8%)

 

(40,50]

467 (20.7%)

116 (19.3%)

34 (18.1%)

317 (21.7%)

 

(50,60]

245 (10.9%)

61 (10.1%)

13 (6.9%)

171 (11.7%)

 

(60,100)

90 (4.0%)

28 (4.7%)

5 (2.7%)

57 (3.9%)

 

Sex

    

0.01

Female

1,720 (76.3%)

486 (80.9%)

141 (75.0%)

1,093 (74.7%)

 

Male

533 (23.7%)

115 (19.1%)

47 (25.0%)

371 (25.3%)

 

Marital status

     

Divorced

41 (1.8%)

13 (2.2%)

1 (0.5%)

27 (1.8%)

 

Married

1,080 (47.9%)

310 (51.6%)

86 (45.7%)

684 (46.7%)

 

Separated

69 (3.1%)

31 (5.2%)

10 (5.3%)

28 (1.9%)

 

Single

795 (35.3%)

170 (28.3%)

68 (36.2%)

557 (38.0%)

 

Widowed

268 (11.9%)

77 (12.8%)

23 (12.2%)

168 (11.5%)

 

ART regimen

     

TLD

1,705 (75.7)

311 (51.7)

136 (72.3)

1,258 (85.9)

 

TLE

512 (22.7)

282 (46.9)

50 (26.6)

180 (12.3)

 

ALD

2 (0.1)

0 (0.0)

0 (0.0)

2 (0.1)

 

ALE

1 (< 0.1)

0 (0.0)

0 (0.0)

1 (< 0.1)

 

Others

33 (1.6)

8 (1.3)

2 (1.1)

23 (1.5)

 

ART duration (months)

    

0.10

(≤ 3)

196 (8.7%)

64 (10.6%)

20 (10.6%)

112 (7.7%)

 

(3–6]

116 (5.1%)

32 (5.3%)

11 (5.9%)

73 (5.0%)

 

(6–12]

186 (8.3%)

50 (8.3%)

19 (10.1%)

117 (8.0%)

 

(12–24]

321 (14.2%)

67 (11.1%)

24 (12.8%)

230 (15.7%)

 

(> 24)

1,434 (63.6%)

388 (64.6%)

114 (60.6%)

932 (63.7%)

 
  1. TLD: tenofovir + lamivudine + dolutegravir; TLE: tenofovir + lamivudine + efavirenz
  2. ALD: abacavir + lamivudine + dolutegravir; ART: antiretroviral therapy
  3. ALE: abacavir + lamivudine + efavirenz